HB 664 would amend New Hampshire’s childhood immunization law to prohibit any childhood vaccine requirement from including a vaccine that has not been tested with an inert placebo in a clinical trial. In practical terms, the bill would add a new limitation to RSA 141-C:20-a, narrowing the vaccines that could be required for children under state immunization requirements.
The bill does not repeal childhood immunization requirements generally; instead, it conditions those requirements on the type of clinical testing a vaccine has undergone. It would take effect 60 days after passage and would apply to the state’s existing framework for childhood vaccine mandates, including school and other immunization-related requirements governed by state law.
Impact
If enacted, HB 664 would modify RSA 141-C:20-a by adding a new paragraph restricting the state’s authority to require certain vaccines for children. The practical effect would be to limit mandatory childhood immunizations to vaccines that have been tested with an inert placebo in clinical trials, potentially affecting which vaccines can be included in school-entry or other childhood immunization schedules under New Hampshire law. The bill would not itself create a new vaccine program or mandate, but would impose a new legal condition on existing immunization requirements.
Sentiment
There is limited recorded committee or floor discussion in the provided materials, and no vote history is available. Based on the bill’s introduction and subject matter, the measure appears to reflect concern among supporters about vaccine testing standards and parental choice, while likely drawing skepticism from public health advocates who generally support existing immunization schedules and may view the placebo-testing requirement as restrictive or inconsistent with current vaccine development practices. Because no transcripts or votes are provided, the overall sentiment cannot be measured beyond the bill’s text and sponsorship.
Contention
The central point of contention is the bill’s requirement that any vaccine included in childhood immunization mandates must have been tested with an inert placebo in clinical trials. Supporters are likely to argue this is a safety and transparency safeguard, while opponents may contend that it would exclude vaccines that are widely used and approved under existing regulatory standards but were not tested in the exact manner the bill requires. The dispute therefore turns on vaccine safety methodology, the scope of state authority over immunization requirements, and the practical effect on school and childhood vaccination policy.